Related Experiment Video

Updated: Oct 2, 2026

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
10:31

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

Published on: April 20, 2018

[Pharmacologic interactions between quinolones and oral hypoglycemic agents. An experimental study on rabbits]

C Losasso1, A Loffreda, M Angrisani

  • 1Istituto di Farmacologia e Tossicologia, Facoltà di Medicina e Chirurgia, Il Università degli Studi di Napoli.

Giornale Italiano Di Chemioterapia
|January 1, 1992
PubMed

Insights

Nalidixic acid, an antibiotic, significantly increases the blood-sugar-lowering effects of oral hypoglycemic drugs at therapeutic doses. Other quinolones showed this interaction only at high, non-clinical dosages.

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Microbiology

Context:

  • Antibiotics and oral hypoglycemic agents can lead to significant pharmacological interactions.
  • Understanding these interactions is crucial for patient safety and effective treatment regimens.

Purpose:

  • To experimentally investigate potential pharmacological interactions between specific quinolone antibiotics (nalidixic acid, ofloxacin, pefloxacin, sparfloxacin) and oral hypoglycemic drugs (phenphormine, glibenclamide).

Summary:

  • Nalidixic acid, at therapeutic doses, was found to increase the hypoglycemic effect of phenphormine and glibenclamide.
  • Ofloxacin, pefloxacin, and sparfloxacin demonstrated an increased hypoglycemic effect on phenphormine and glibenclamide, but only at high dosages not typically used in clinical practice.

Impact:

  • Highlights the clinically relevant interaction between nalidixic acid and oral hypoglycemic agents.
  • Suggests caution when co-administering nalidixic acid with drugs like phenphormine and glibenclamide to avoid hypoglycemia.
  • Provides evidence for dose-dependent interactions with other quinolones, informing future drug safety assessments.

More Related Videos

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits10:25

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...